Shinobi Therapeutics, Inc.
PrivateLast Round
Grant
Aug 6, 2024
Total Funding Raised
$142.3M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Shinobi Therapeutics, Inc. is a biotechnology company that develops off-the-shelf, immune-evasive iPSC-derived cell therapies for the treatment of cancer and autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Shinobi Therapeutics, Inc. Comparables
Compare Shinobi Therapeutics, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Shoreline Biosciences | 83% | |
| Notch Therapeutics | 81% | |
| HebeCell | 79% |
Shinobi Therapeutics, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Aug 6, 2024 | ||||
| Series A Extension | Aug 6, 2024 | ||||
| Series A | Dec 12, 2023 | ||||
| Series B | Feb 21, 2022 | ||||
| Series A Extension | Oct 29, 2021 | ||||
Series A | Nov 20, 2019 |
Shinobi Therapeutics, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Chushin Venture Capital | Series A |
| Japan Agency for Medical Research and Development | Grant |
| EQT Life Sciences | Series A |
| JIC Venture Growth Investments | Series A |
| Yosemite | Series A Extension |
| Eight Roads Ventures Japan | Series B, Series A |
| Miraidoa | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors increased 55% MoM.
- Apr 16, 2026
Monthly visitors grew 247% MoM, reaching 8.7K.
Shinobi Therapeutics, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Shinobi Therapeutics, Inc.'s valuation, stock price, and market status.
Is Shinobi Therapeutics, Inc. a public or private company?
Shinobi Therapeutics, Inc. is a private company.
What is the current stock price of Shinobi Therapeutics, Inc.?
Shinobi Therapeutics, Inc. is a private company, so its shares have no public market price. Caplight tracks Shinobi Therapeutics, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Shinobi Therapeutics, Inc. worth (valuation)?
Valuation information for Shinobi Therapeutics, Inc. is not publicly available.
Can I buy Shinobi Therapeutics, Inc. stock?
Shinobi Therapeutics, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Shinobi Therapeutics, Inc.'s last funding round?
Shinobi Therapeutics, Inc.'s most recent funding round was Grant on August 6, 2024.
Who are the main investors in Shinobi Therapeutics, Inc.?
Key investors in Shinobi Therapeutics, Inc. include EQT Life Sciences, Eight Roads Ventures Japan, F-Prime Capital.
Will Shinobi Therapeutics, Inc. IPO soon?
No public IPO plans have been announced for Shinobi Therapeutics, Inc..
How can I track Shinobi Therapeutics, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Shinobi Therapeutics, Inc.'s shares on secondary markets.